$27.00+1.45 (+5.68%)
Hemab Therapeutics Holdings, Inc.
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $0 | $0 |
| Gross Profit | — | — |
| Operating Income | -$23.61M↓ | -$16.56M |
| Net Income | -$22.69M↓ | -$15.31M |
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its pr...
Hemab Therapeutics (NASDAQ:COAG) Chief Executive Officer Benny Sorensen outlined the company’s development plans following its recent initial public offering during a fireside chat with Jefferies biotech analyst Maury Raycroft. Sorensen said Hemab is pursuing a strategy to build “a multiple product
Hemab Therapeutics Holdings has completed its initial public offering and begun trading on the Nasdaq Global Select Market under the ticker NasdaqGS:COAG. The stock is currently priced at $34.0 per share. The company reports a year to date return of 88.9%. For investors tracking new biotech listings, Hemab Therapeutics Holdings arriving on the Nasdaq Global Select Market puts a fresh ticker on the radar. At a share price of $34.0 and a reported year to date return of 88.9%, NasdaqGS:COAG is...